- Home
- PASG vs RLYB Comparison
PASG vs RLYB Comparison
Compare PASG & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | RLYB |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 24.1M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PASG | RLYB |
|---|---|---|
| Price | $11.77 | $0.69 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $34.50 | N/A |
| AVG Volume (30 Days) | 50.9K | ★ 198.6K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $5.12 | $0.22 |
| 52 Week High | $20.20 | $1.08 |
Technical Indicators
Market Signals| Indicator | PASG | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 67.97 | 47.14 |
| Support Level | $9.56 | $0.64 |
| Resistance Level | $11.50 | $0.80 |
| Average True Range (ATR) | 1.03 | 0.05 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 98.12 | 29.11 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.